Leveraging its cutting edge magnetic nanotechnology Ferrologix will help accelerate & scale emerging diagnostics & therapeutics.
Ferrologix was founded in 2015 based on a core technology Dr. Coleman Murray invented called digital magnetic sorting or ratcheting cytometry. The technology uses chips composed of ferromagnetic microstructure arrays which can be used to concentrate and manipulate magnetic fields at microscopic scales. By subjecting the chips to a rotating, aka ratcheting, magnetic field, cells which have been magnetically tagged can be precisely transported as they jump from element to element. This cell manipulation process can be used to precisely transport and filter millions of cells simultaneously.
Seeing the impact that the technology could make in the biotechnology field, the technology inventors founded Ferrologix Inc and began commercial translational efforts. After its founding Tim Tiemann joined the Ferrolgix team as CEO to spearhead business development and commercial translational efforts. To date the company has been awarded several SBIR grants and contracts to accelerate its technology towards real world impact.
Chief Executive Officer
Tim Tiemann serves as CEO for Ferrologix Inc. and has over twenty years experience in the biotech industry. He has led several successful biotech ventures and tech startups launching from companies such as Bayer and Motorola. He brings business development & leadership experience to the Ferrologix team.
Coleman Murray, Ph.D.
Founder & Chief Operational Officer
Dr. Coleman Murray serves as COO and co-founder of Ferrologix Inc. He has a background in lab automation and applying microelectromechanical systems (MEMS) towards healthcare products. He received his Ph.D. in 2015 under the mentorship of Professor Dino Di Carlo where he developed the ratcheting cytometry platform which formed Ferrologix's core technology.
Dino Di Carlo, Ph.D.
Founder & Scientific Advisor
Professor Dino Di Carlo serves as co-founder and scientific advisory to Ferrologix. He holds a faculty position at the UCLA Department of Bioengineering and has pioneered the development of multiple micro-technologies, resulting in the founding and launch of six startup companies.
Director of Bioassay Development
Savannah Bshara-Corson serves as Director of Bioassay Development with a background in T cell biology. She received her Bachelor's Degree in Molecular and Cellular Biology and Master's degree in Immunology. She is currently spearheading Ferrologix DMS cell purification platforms for rare cell isolation and multitarget cell sorting.
Andrew Burwell is a Research Assistant with Ferrologix. He has a B.S. in Biological Sciences from PLNU and works on a variety of R&D projects in the Ferrologix technology suite. He is currently working on Ferrologix Single Cell Secretion detection platform.